Is AstraZeneca plc’s Latest Director Deal A Game-Changer?

With AstraZeneca plc (LON:AZN)’s CEO buying shares this week, is it a significant event for investors?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaHaving been the subject of numerous bid approaches in recent months from US peer Pfizer, AstraZeneca (LSE: AZN) (NYSE: AZN.US) has now seen CEO Pascal Soriot buy around £2 million of shares in the company. The price he paid was £43.45 per share, which is within 10% of their five-year high. Does this mean that even after share price gains of 38% over the last year he is still extremely bullish on the company’s prospects? Or should investors in AstraZeneca lock in recent gains?

A New Pipeline

Clearly, AstraZeneca remains something of a turnaround story. Although over the medium to long term its pipeline is now in a much better state than it was even a year or two ago after the company has made a number of key acquisitions, AstraZeneca’s short-term outlook remains rather disappointing. For example, earnings per share (EPS) are expected to fall by 15% this year and by 3% next year, which indicates that the CEO is looking beyond the next couple of years and focusing on the longer term potential of the pipeline.

Short Term vs Long Term

Indeed, the fact that AstraZeneca’s CEO has bought shares in the company indicates that there are no fresh takeover talks taking place. Therefore, with earnings set to decline over the next couple of years, it could be the case that AstraZeneca’s current valuation comes under pressure. That’s because it was boosted by the Pfizer bids and it would not be a major surprise for it to drift back towards pre-bid levels. Of course, that’s not to say that AstraZeneca doesn’t have growth potential over the long run (it certainly does), but it does mean that the pace of recent gains may not be repeated until the company starts to deliver on its potential.

Sector Peers

Clearly, AstraZeneca has significant long term potential and continues to boost its pipeline, which bodes well for investors. However, sector peers GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Smith & Nephew (LSE: SN) could also prove to be winning plays in the long run. For example, GlaxoSmithKline currently offers a better yield than AstraZeneca (5.2% versus 3.8% for AstraZeneca), as well as a lower price to earnings (P/E) ratio of 15.2 (versus 17.4 for AstraZeneca). GlaxoSmithKline also has a strong pipeline and has cash to burn after the sale of its Lucozade and Ribena brands.

Similarly, Smith & Nephew could also prove to be a strong long-term performer. Its business model is more stable than that of AstraZeneca, with the company focusing on wound care and orthopaedic reconstruction as opposed to the development of new drugs. Smith & Nephew trades on a relatively high P/E of 20.8, but offers double-digit EPS growth over the next two years. This means that shares in the company could continue to rise after gaining 40% in the last year alone.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter owns shares in GlaxoSmithKline and AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline and owns shares in Smith & Nephew.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »